Maritza Gomez Montiel
Maritza Gomez Montiel's purchase track record
Maritza Gomez Montiel has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/10/2023 | RCL | $104K | -10.6% | +16.8% | +11.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royal Caribbean Stock Rises 12% as Earnings Outlook Improves. Recent news highlights Royal Caribbean's 12% stock rise over the past month, outperforming the broader market. The company faces questions regarding its expanded Europe lineup and whether it can continue to beat earnings estimates. Industry observers suggest the cruise sector may see calmer waters in upcoming quarters, supporting the recent stock momentum.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
McCormick Analysts Lower Targets After Q3 Results. McCormick shares have come under pressure as several analysts, including UBS and TD Cowen, lowered their price targets following third-quarter results. While BNP Paribas maintained a positive outlook, the broader trend reflects reduced expectations for near-term growth. The company has also replaced its auditor with KPMG and reaffirmed its overall financial outlook despite the recent stock decline.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AptarGroup Secures CE Marking for LuerVax as UBS Starts Coverage. AptarGroup announced that its LuerVax product and accompanying spray divider have received CE marking, a regulatory step that supports vaccine developers. Separately, UBS initiated coverage on the stock with a neutral rating and a price target of $135. The company's average analyst target remains $162.00, with a range extending to $220.00.
Transaction History
| VSNT | ▲ Buy | Grant | 5,119 | $185K | 6/26/2026 | View on chart |
| RCL | ▼ Sell | Tax Withholding | 78 | $22K | 5/28/2026 | View on chart |
| RCL | ▲ Buy | Grant | 831 | $0 | 5/28/2026 | View on chart |
| RCL | ▼ Sell | Open Market | 1,385 | $453K | 2/17/2026 | View on chart |
| MKC | ▲ Buy | Option Exercise | 2,222 | — | 2/15/2026 | View on chart |
| VSNT | ▲ Buy | Grant | 2,378 | — | 1/9/2026 | View on chart |
| RCL | ▼ Sell | Open Market | 1,100 | $310K | 11/3/2025 | View on chart |
| RCL | ▲ Buy | Grant | 870 | $0 | 5/28/2025 | View on chart |
| RCL | ▼ Sell | Open Market | 1,500 | $364K | 5/12/2025 | View on chart |
| MKC | ▲ Buy | Option Exercise | 5,912 | $313K | 4/1/2025 | View on chart |
| MKC | ▼ Sell | Open Market | 5,912 | $489K | 4/1/2025 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,344 | $0 | 3/15/2025 | View on chart |
| MKC | ▲ Buy | Option Exercise | 3,000 | $150K | 8/15/2024 | View on chart |
| MKC | ▲ Buy | Option Exercise | 6,816 | $334K | 8/15/2024 | View on chart |
| MKC | ▼ Sell | Open Market | 6,816 | $524K | 8/15/2024 | View on chart |
| MKC | ▼ Sell | Open Market | 3,000 | $231K | 8/15/2024 | View on chart |
| CCZ | ▲ Buy | Grant | 390 | $0 | 3/31/2024 | View on chart |
| MKC | ▲ Buy | Option Exercise | 7,000 | $350K | 3/28/2024 | View on chart |
| MKC | ▼ Sell | Open Market | 7,000 | $539K | 3/28/2024 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,255 | $0 | 3/15/2024 | View on chart |
| RCL | ▲ Buy | Grant | 2,372 | $0 | 2/8/2024 | View on chart |
| CCZ | ▼ Sell | Tax Withholding | 49 | $2K | 11/20/2023 | View on chart |
| CCZ | ▲ Buy | Grant | 5,240 | $0 | 11/20/2023 | View on chart |
| RCL | ▲ Buy | Open Market | 1,000 | $104K | 8/10/2023 | View on chart |
| ATR | ▲ Buy | Grant | 1,266 | $0 | 5/3/2023 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,044 | — | 3/15/2023 | View on chart |
| ATR | ▼ Sell | Open Market | 1,500 | $172K | 2/21/2023 | View on chart |
| RCL | ▲ Buy | Grant | 2,682 | $0 | 2/9/2023 | View on chart |
| CCZ | ▲ Buy | Grant | 447 | $0 | 12/31/2022 | View on chart |
| CCZ | ▼ Sell | Tax Withholding | 1 | $34 | 11/20/2022 | View on chart |
| CCZ | ▲ Buy | Grant | 5,677 | $0 | 11/20/2022 | View on chart |
| CCZ | ▲ Buy | Grant | 533 | $0 | 9/30/2022 | View on chart |
| CCZ | ▲ Buy | Grant | 391 | $0 | 6/30/2022 | View on chart |
| ATR | ▲ Buy | Grant | 1,302 | $0 | 5/4/2022 | View on chart |
| CCZ | ▲ Buy | Grant | 334 | $0 | 3/31/2022 | View on chart |
| MKC | ▲ Buy | Option Exercise | 1,139 | — | 3/15/2022 | View on chart |
| ATR | ▼ Sell | Open Market | 1,092 | $129K | 2/22/2022 | View on chart |
| RCL | ▲ Buy | Grant | 2,256 | $0 | 2/10/2022 | View on chart |
| CCZ | ▲ Buy | Grant | 310 | $0 | 12/31/2021 | View on chart |
| CCZ | ▲ Buy | Grant | 3,786 | $0 | 11/20/2021 | View on chart |
| CCZ | ▼ Sell | Tax Withholding | 15 | $773 | 11/20/2021 | View on chart |
| MKC | ▼ Sell | Open Market | 394 | $32K | 10/28/2021 | View on chart |
| MKC | ▼ Sell | Open Market | 3,098 | $251K | 10/26/2021 | View on chart |
| MKC | ▲ Buy | Option Exercise | 3,000 | $118K | 10/25/2021 | View on chart |
| MKC | ▼ Sell | Open Market | 3,000 | $241K | 10/25/2021 | View on chart |
| CCZ | ▲ Buy | Grant | 279 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Morgan Stanley initiates VSNT coverage with Equal-Weight rating
Morgan Stanley has started covering Versant Media Group, assigning it an Equal-Weight rating and a $38 price target. This new analyst coverage provides a fresh perspective on the stock, which currently trades near its support level. The move adds to the existing analyst consensus, where the average target price stands at $44.57.
Morgan Stanley initiates VSNT coverage with Equal-Weight rating. Morgan Stanley has started covering Versant Media Group, assigning it an Equal-Weight rating and a $38 price target. This new analyst coverage provides a fresh perspective on the stock, which currently trades near its support level. The move adds to the existing analyst consensus, where the average target price stands at $44.57.